Literature DB >> 7438675

Effects of thyroid dysfunction on propranolol kinetics.

J G Riddell, J D Neill, J G Kelly, D G McDevitt.   

Abstract

Propranolol kinetics was studied in six hyperthyroid and six hypothyroid patients who received single oral and intravenous doses of propranolol when they had thyroid dysfunction and again when they had become euthyroid. Change in thyroid status from hyperthyroid to euthyroid produced no change in the elimination half-life (t 1/2) of oral propranolol (3.2 +/- 0.5 to 4.1 +/- 0.7 hr), the oral clearance (38.4 +/- 7.3 to 27.4 +/- 2.4 ml/min/kg), the elimination t 1/2 of intravenous propranolol (2.5 +/- 0.3 to 3.5 +/- 0.7 hr), and the apparent volume of distribution (4.8 +/- 0.4 to 3.8 +/- 0.5 l/kg). The systemic clearance of propranolol, however, was greater when the patients were hyperthyroid (20.8 +/- 2.5 ml/min/kg) than when they had become euthyroid (11.7 +/- 1.7 ml/min/kg). The elimination t 1/2 after oral propranolol was longer in the hypothyroid (3.7 +/- 0.5 hr) than in the euthyroid state (2.0 +/- 0.1 hr). No other changes were observed in the kinetic parameters measured when these hypothyroid patients had become euthyroid. Adequate beta-adrenoceptor blockade in hyperthyroid patients may require higher propranolol dosage than expected.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438675     DOI: 10.1038/clpt.1980.204

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.

Authors:  J Feely
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

3.  Clinical pharmacology. Elimination of drugs.

Authors:  H E Barber; J C Petrie
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-07

4.  Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol.

Authors:  B Hallengren; O R Nilsson; B E Karlberg; A Melander; L Tegler; E Wåhlin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

6.  A study of long acting propranolol in the early management of hyperthyroidism.

Authors:  G R Jones; J H Lazarus; D Wynford-Thomas
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

Review 7.  Use of beta-adrenoceptor blocking drugs in hyperthyroidism.

Authors:  J Feely; N Peden
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

8.  Pharmacokinetics of propranolol and sotalol in hyperthyroidism.

Authors:  A Aro; M Anttila; T Korhonen; H Sundquist
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.